Day One Biopharmaceuticals Future Growth
Future criteria checks 5/6
Day One Biopharmaceuticals is forecast to grow earnings and revenue by 56.6% and 33.6% per annum respectively. EPS is expected to grow by 56.9% per annum. Return on equity is forecast to be -21.8% in 3 years.
Key information
56.6%
Earnings growth rate
56.9%
EPS growth rate
Biotechs earnings growth | 27.3% |
Revenue growth rate | 33.6% |
Future return on equity | -21.8% |
Analyst coverage | Good |
Last updated | 31 Jan 2025 |
Recent future growth updates
Recent updates
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Jan 07Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 417 | 62 | 174 | 131 | 6 |
12/31/2026 | 296 | -22 | 31 | -13 | 9 |
12/31/2025 | 165 | -109 | -73 | -87 | 10 |
12/31/2024 | 122 | -68 | -172 | -37 | 10 |
9/30/2024 | 102 | -84 | -162 | -89 | N/A |
6/30/2024 | 8 | -167 | -197 | -177 | N/A |
3/31/2024 | N/A | -209 | -174 | -171 | N/A |
12/31/2023 | N/A | -189 | -150 | -147 | N/A |
9/30/2023 | N/A | -175 | -144 | -141 | N/A |
6/30/2023 | N/A | -166 | -127 | -127 | N/A |
3/31/2023 | N/A | -157 | -114 | -114 | N/A |
12/31/2022 | N/A | -142 | -110 | -110 | N/A |
9/30/2022 | N/A | -124 | -88 | -88 | N/A |
6/30/2022 | N/A | -105 | -77 | -77 | N/A |
3/31/2022 | N/A | -183 | -60 | -60 | N/A |
12/31/2021 | N/A | -171 | -57 | -49 | N/A |
9/30/2021 | N/A | -183 | -49 | -41 | N/A |
6/30/2021 | N/A | -167 | -41 | -33 | N/A |
3/31/2021 | N/A | -54 | -29 | -21 | N/A |
12/31/2020 | N/A | -41 | -14 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DAWN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: DAWN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DAWN is expected to become profitable in the next 3 years.
Revenue vs Market: DAWN's revenue (33.6% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: DAWN's revenue (33.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DAWN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 05:16 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Day One Biopharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Naureen Quibria | Capital One Securities, Inc. |
Andrea Newkirk | Goldman Sachs |